* Biomira Inc., of Edmonton, Alberta, said preclinical data on a lymphoma vaccine showed that a single immunization caused a patient's own immune system to attack residual tumor cells and prevent further growth following chemotherapy or monoclonal antibody treatment. The vaccine uses a liposome carrier containing minimal amounts of cancer-associated antigen and the immune enhancer interleukin-2. The treatment is being developed under a Collaborative Research and Development Agreement between the National Cancer Institute, of Frederick, Md., and Biomira USA Inc., a subsidiary of Biomira.
* CytRx Corp., of Atlanta, said it completed redemption of convertible debentures from its October 1997 $2 million private placement. A total of $500,000 was converted into stock and $1.5 million was redeemed by the company.
* American Biogenetic Sciences Inc., of Copiague, N.Y., completed a $4 million private placement of convertible debentures plus warrants. The company will use the money for marketing and product development, as well as to support its acquisition strategy and general working capital needs.
* Aquila Biopharmaceuticals Inc., of Worcester, Mass., adopted a shareholder rights plan designed to protect the long-term interests of Aquila and its stockholders in the event of an unsolicited acquisition attempt. The plan was not adopted in response to any takeover effort.
* Cypros Pharmaceutical Corp., of Carlsbad, Calif., received European regulatory approval to start Phase II trials of Cordox in heart transplant patients. The trials will evaluate the cardioprotective effects of Cordox prior to and during transplantation. It also will evaluate the drug's ability to reduce ischemia-induced complications and the incidence of early graft dysfunction. The study will take place in the U.K. Cordox is a naturally occurring, high-energy intermediate of glycolysis, fructose 1-6 diphsophate, that appears to facilitate production of high-energy metabolites under circumstances where oxygen supply is limiting.
* Cel-Sci Corp., of Alexandria, Va., received a $100,000 Phase I Small Business Innovation Research grant from the National Institute of Allergy and Infectious Diseases to fund animal studies of its herpes simplex vaccine. The company said the vaccine is based on its Leaps technology (Ligand Epitope Antigen Presentation System) and consists of two protein pieces, a copy of a portion of the herpes simplex virus and a T cell binding ligand.